CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 37,656 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 37,656 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $22,593.60. Following the completion of the sale, the chief executive officer now directly owns 995,195 shares in the company, valued at approximately $597,117. The trade was a 3.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock opened at $0.67 on Friday. The company has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.99. The stock has a market capitalization of $53.34 million, a PE ratio of 3.92 and a beta of 1.05. CytomX Therapeutics, Inc. has a 52-week low of $0.56 and a 52-week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. As a group, equities research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CTMX. StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, March 10th. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CytomX Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $5.02.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. increased its holdings in CytomX Therapeutics by 1.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 16,359 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of CytomX Therapeutics by 16.0% during the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 20,746 shares during the last quarter. Miller Financial Services LLC bought a new stake in shares of CytomX Therapeutics in the fourth quarter worth approximately $26,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of CytomX Therapeutics by 10.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares during the last quarter. Finally, Prudential Financial Inc. lifted its position in CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 27,800 shares during the period. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.